Exact Sciences Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Go Beyond the Preview – Access the Full Value Chain Analysis
This Exact Sciences Value Chain Analysis gives you a clear, structured view of how the company creates value across support and primary activities. The page already shows a real preview of the actual report, so you can review the content and format before buying. Purchase the full version to get the complete ready-to-use analysis.
Support Activities
Firm Infrastructure
Exact Sciences keeps firm infrastructure centralized, with finance, legal, compliance, and quality teams steering a regulated diagnostics platform. That matters because Cologuard and Oncotype DX must stay aligned with payer rules and clinical standards while Exact Sciences reported 2024 revenue of $2.76 billion and a year-end cash and equivalents balance of $809 million. Central control also supports capital discipline, which is critical after Exact Sciences posted a 2024 net loss of $1.69 billion.
Human Resource Management
Exact Sciences depends on lab scientists, bioinformaticians, medical affairs staff, reimbursement specialists, and a field sales force to keep Cologuard and Oncotype DX accurate and trusted. In its latest full year, Exact Sciences generated about $2.8 billion of revenue, so hiring and training directly support throughput, payer coverage, and physician adoption. Strong HR also helps scale screening and precision oncology without slipping on quality.
Technology Development
Exact Sciences keeps Technology Development at the core of its value chain by funding assay R&D, clinical validation, and data analytics for Cologuard and Oncotype DX. In fiscal 2025, this work continued to support stronger test performance, broader payer evidence, and new cancer care products, with Exact Sciences serving millions of patients across its screening and precision oncology tests. That mix turns lab science into coverage, adoption, and pipeline growth.
Procurement
In Exact Sciences, procurement covers reagents, kit components, lab consumables, and instruments from qualified suppliers. Tight sourcing helps keep test quality high, hold down cost per test, and cut supply interruptions in a regulated lab workflow. In 2025, that matters more as volume, traceability, and supplier control shape both service levels and margin discipline.
Exact Sciences Tightens Controls to Support Growth and Margin Discipline
Exact Sciences centralizes finance, legal, compliance, and quality, which matters for a regulated diagnostics business that reported $2.76 billion in revenue and $809 million in cash and equivalents at year-end 2024. Its support functions help keep Cologuard and Oncotype DX aligned with payer rules, lab standards, and cost control after a $1.69 billion net loss. Hiring, training, and supplier control also support test volume and margin discipline.
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Exact Sciences runs inbound logistics through controlled shipping for patient samples, collection kits, and consumables, because stool, tissue, and blood specimens must stay intact from pickup to lab. Chain-of-custody controls matter here: every handoff affects test validity, turnaround time, and reimbursement risk. In 2025, this front-end flow supported Exact Sciences revenue of about $2.7 billion, so even small shipping errors can hit scale and margin.
Operations
In 2025, Exact Sciences converts specimens into clinical reports through lab processing, molecular analysis, bioinformatics, and final quality review. For Cologuard and Oncotype DX, fast turnaround and high accuracy matter because clinicians rely on them for screening and treatment decisions, and payers expect consistent test quality. Its scale shows in FY2025, when the Exact Sciences lab network kept moving high-volume diagnostics for patients aged 45 to 75 and oncology care.
Outbound Logistics
Exact Sciences' outbound logistics is mostly digital: results go electronically to ordering physicians, health systems, and patients where appropriate, which cuts delay and manual handoff risk.
Its kit-shipping and return flow keeps patient samples moving back to the lab fast, which matters in a 2025 business that still relies on high-volume test execution and tight turnaround.
That model supports service speed and lower handling cost, while also improving follow-up for screening, diagnosis, and treatment decisions.
Marketing and Sales
Exact Sciences leans on physician education, oncology and primary-care outreach, payer engagement, and screening awareness to drive orders for Cologuard and Oncotype DX. This step matters because many tests are only used after providers understand the right patient, the clinical benefit, and reimbursement rules. In 2025, that makes demand creation a core sales task, not a support function, because awareness and coverage can decide whether a test gets ordered at all.
Service
Exact Sciences' service arm helps patients and providers with pre-test education, billing help, prior-authorization support, and result interpretation, so the test feels easier to use in 2025. That post-test support reduces friction, cuts drop-off, and helps protect repeat ordering across Cologuard and Oncotype DX workflows. It also makes the brand stickier when buyers compare not just the test, but the full care path.
Exact Sciences FY2025: Sample-to-Report Engine Drove $2.7B Revenue
Exact Sciences' primary activities in FY2025 turned samples into clinical reports, then pushed results electronically to doctors and patients. Strong outreach and payer work kept Cologuard and Oncotype DX orders flowing, while support services reduced billing and authorization friction. FY2025 revenue was about $2.7 billion.
| FY2025 | Value |
|---|---|
| Revenue | $2.7B |
Full Version Awaits
Exact Sciences Reference Sources
This is the actual Exact Sciences Value Chain Analysis document you'll receive upon purchase – no surprises, just professional quality. The preview below is taken directly from the full report, so what you see here is exactly what you'll get. Purchase unlocks the complete version immediately.
Frequently Asked Questions
It shows how Exact Sciences turns 2 core commercial franchises into reimbursed diagnostic revenue. Cologuard covers screening, and Oncotype DX uses a 21-gene assay with a 0-100 Recurrence Score. The value chain depends on payer coverage, test accuracy, and efficient lab turnaround at scale, not physical inventory.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.